Corgenix Partners with AXA Diagnostics on SkyLAB 752™ Automated Testing Platform

Corgenix Partners with AXA Diagnostics on SkyLAB 752™ Automated Testing Platform

October 20, 2011

Distribution agreement enables Corgenix to expand test offerings, compete for high-volume testing lab business.

Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has entered into a U.S. distribution agreement with strategic partner AXA Diagnostics Srl of Pomezia, Italy. Under terms of the agreement, Corgenix will market AXA Diagnostics’ proprietary SkyLAB 752™ ELISA/IFA Analyzer on a non-exclusive basis in the United States.

The SkyLAB 752 is the first automated microplate processing instrument that can independently multitask performing all functions at the same time-a new feature not found on other instrumentation. The new, high-throughput ELISA (enzyme-linked immunosorbent assay) and IFA (immunofluorescence assay) platform can process up to 7 microplates or 28 IFA slides simultaneously. Due to its state-of-the-art pipetting system the SkyLAB 752 can easily process Corgenix rapid ELISA tests for significant time and cost savings to the laboratories, giving Corgenix products a significant advantage over competitive test kits with longer incubation times.

“The breakthrough technology and unique features of the SkyLAB 752 will allow us to market this instrument in conjunction with Corgenix ELISA kits and offer higher throughput and labor-saving advantages to our customers,” said Corgenix President and CEO Douglass Simpson. “We are extremely pleased that AXA Diagnostics has chosen to establish this relationship with Corgenix.”

Simpson said the SkyLAB 752 will be available for evaluation at external sites by year’s end and will be registered as a Class I Device with the FDA by Dec. 31, 2011.

AXA Diagnostics General Manager Silvio Furino said Corgenix has built a strong reputation for providing innovative healthcare products to its customers, which makes them an ideal partner for AXA Diagnostics.

“We’re excited to be establishing this strategic alliance with Corgenix, enabling the company to offer its customers a unique assay automation solution,” Furino said. “Our new SkyLAB 752 instrument gives Corgenix the ability to automate their rapid immunoassay kits that, until now, were not able to be used in conjunction with other instrumentation available in the market.

Key differentiating features of the SkyLAB 752 analyzer allow a full microplate to be loaded in approximately eight minutes, which is about half the time of most other analyzers on the market. The SkyLAB instrument also incorporates incubation options that include: heating and shaking; the use of standard disposable pipette tips that eliminate carryover; clot detection; bubble detection; positive sample ID; and custom software that allows remote diagnostics and communication with LIS software. The SkyLAB 752 uses a state-of-the-art LED microplate reading system that allows precision, reduced maintenance and a 3.5 OD dynamic range. For more information, visit the SkyLAB 752 website at www.skylabteam.org.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

About AXA Diagnostics Srl

AXA Diagnostics is a private company located in Pomezia, Italy that markets proprietary instrumentation and specialized diagnostic tests, with an emphasis on autoimmune in vitro diagnostic products. AXA Diagnostics sells over 300 diagnostic products through a network of distributors in Europe and other international markets. AXA Diagnostics has obtained certification for the management of its quality system according to the requirements of UNI EN ISO 13485:2004. More information on AXA Diagnostics is available at www.axadiagnostics.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO
Phone: 303-453-8903
E-mail: wcritchfield@corgenix.com

Media Contact
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor
Phone: 303-623-1190 x230
E-mail: dan@armadamedical.com

Corgenix Teams Up with Strategic Partners at AACC

PRESS RELEASE

For Immediate Release
Corgenix Teams Up with Strategic Partners at AACC Clinical Lab Expo 2011

Corgenix to exhibit AspirinWorks Test and other specialized diagnostic kits

DENVER — July 22, 2011 — Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners AXA Diagnostics and ELITech Group at the AACC Clinical Lab Expo 2011 in Atlanta, GA.

Corgenix will exhibit its AspirinWorks® Test at AACC July 24-July 28 in booth No. 444.
Also on display in the Corgenix booth will be the SkyLAB752TM instrument from strategic partner AXA Diagnostics. SkyLAB Team staff will present the new, high-throughput ELISA and IFA automated platform, which can process up to 7 microplates or 28 IFA slides simultaneously.

Additionally, Corgenix will have a presence in strategic partner ELITech Group’s booth No. 542. In 2010 the two companies entered into a formal strategic alliance to co-develop new diagnostic tests. The alliance included an ELITech Group investment in Corgenix and the expansion of Corgenix’s distribution network for its test kits, including the AspirinWorks Test.

Corgenix will have representatives available during the conference to answer questions about the AspirinWorks Test and other products, including its diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen, which helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of 11-dehydro thromboxane B2 (11-dhTxB2). High levels of 11-dhTxB2, a metabolite of thromboxane — the target of aspirin therapy — heighten the risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

Millions of Americans take a daily aspirin to prevent heart attack or stroke but don’t know if the aspirin is having the desired effect. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness, and therefore reducing the chance of forming a blood clot.

Unlike other functional platelet tests that require freshly drawn blood that must be evaluated in five hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office. Physicians and laboratories interested in ordering the test can call 1-800-729- 5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Media Contact:

Armada Medical Marketing

Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
Email: dan@armadamedical.com

New Aspirin Test Now Available Through Diagnostic Laboratory Medicine

For Immediate Release

New Aspirin Test Now Available Through Diagnostic Laboratory Medicine

AspirinWorks® Test from Corgenix Medical tells doctors, patients if aspirin therapy is working to reduce their risk of heart attack or stroke

BEDFORD, Mass. — May 11, 2011 — A simple urine test that measures aspirin effect is now available in the greater Boston and surrounding area. The AspirinWorks® Test (www.aspirinworks.com) is available to eastern Massachusetts and southern New Hampshire area doctors through Diagnostic Laboratory Medicine (www.dlmlabs.com).

Dr. Joseph Musto, President and Medical Director of Diagnostic Laboratory Medicine, said the AspirinWorks Test is an important addition to the laboratory’s testing services.

“We’re pleased to be one of the first clinical laboratories in the region to offer this valuable test,” said Dr. Musto. “AspirinWorks represents a simple, non-invasive, reliable test for physicians who realize that patients may respond differently to different doses of aspirin. This test truly helps physicians understand their patients’ health on a personal level.”

Aspirin, taken by millions of Americans every day to reduce the risk of heart attack and stroke, works by making blood platelets less sticky and thus less likely to form a blood clot. Major clinical studies have shown that as many as one in four patients are not adequately protected by their aspirin therapy.

The AspirinWorks Test, developed by Corgenix Medical Corp. (OTCQB: CONX.PK), determines the effect of aspirin on platelets by measuring the level of the biomarker called thromboxane B2. The higher the levels of thromboxane B2, the stickier the blood platelets and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient’s therapy, which may be as simple as adjusting the dose.

AspirinWorks is the only FDA-cleared test that measures urinary thromboxane B2 to accurately determine aspirin effect in apparently healthy individuals. Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained at the doctor’s office.

The AspirinWorks Test is reimbursed by most insurance carriers and covered under Medicare. Physicians interested in ordering the test can contact Diagnostic Laboratory Medicine at 1-800- 582-6248 or visit www.dlmlabs.com.

About Diagnostic Laboratory Medicine

Diagnostic Laboratory Medicine (DLM) is a full-service medical laboratory headquartered in Bedford, Mass., with convenient satellite Patient Service Centers located throughout eastern Massachusetts. DLM staff have been exceeding client expectations for more than 30 years, and each specimen is treated as a patient, not a number. DLM’s headquarters location houses multiple departments, providing technical, sales and billing support under one roof. More information is available at www.dlmlabs.com or by calling 800-582-6248 and asking to speak with Dr. Joseph Musto directly.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Media Contact:

Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
Email: dan@armadamedical.com

AspirinWorks® Takes the Stage at Pri-Med Southwest 2011

PRESS RELEASEFor Immediate Release
AspirinWorks® Takes the Stage at Pri-Med Southwest 2011

Test for aspirin effect is simple and non-invasive

DENVER — March 23, 2011 — Corgenix Medical Corporation (OTCQB: CONX.PK), a worldwide developer and marketer of diagnostic test kits, will be exhibiting and offering complimentary testing for its AspirinWorks® Test at Pri-Med® Southwest 2011 in Houston, Texas.

Corgenix representatives will be on-hand during the conference March 24-26 in booth No. 114 at the George R. Brown Convention Center to answer questions about anti-platelet therapy and testing for the aspirin effect. The AspirinWorks Test will be offered to qualified attendees during regular exhibit hours, and test results will be provided after the conference.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen, which helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of 11-dehydro thromboxane B2 (11-dhTxB2). High levels of 11-dhTxB2, a metabolite of thromboxane, the target of aspirin therapy, heighten the risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

Millions of Americans take a daily aspirin to prevent heart attack or stroke but don’t know if the aspirin is having the desired effect. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness, and therefore reducing the chance of forming a blood clot.

Launched in the U.S in June 2007 following FDA 510(k) clearance, the AspirinWorks Test is now available nationwide through major medical laboratories, including Quest Diagnostics,

LabCorp, Health Diagnostic Laboratory, Diagnostic Laboratory Medicine and offered locally in the Houston area as the Aspirin Response Test at SpectraCell Laboratories.

Unlike other functional platelet tests that require freshly drawn blood that must be evaluated in five hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office. Physicians and laboratories interested in ordering the test can call 1-800-729- 5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Media Contact:

Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
Email: dan@armadamedical.com

Corgenix Medical Reaches Milestone in Development of New Test Format

High-speed, automated test format to expand global distribution for AspirinWorks® (11dhTxB2) Test

DENVER — March 3, 2011 — Corgenix Medical Corporation (OTC BB: CONX) has successfully completed the feasibility stage for a new, high-speed automated test format for its AspirinWorks® Test. Developed in collaboration with Randox Laboratories, the new format will make it faster and easier to perform the AspirinWorks Test at clinical laboratories and hospitals around the world.

Millions of Americans take a daily aspirin to prevent heart attack or stroke but don’t know if the aspirin is having the desired effect. AspirinWorks is a simple urine test to measure levels of 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness, and therefore reducing the chance of forming a blood clot. AspirinWorks is the only FDA-cleared test that measures levels of thromboxane metabolite, 11dhTxB2, to determine aspirin effect. Studies show that higher levels of 11dhTxB2 in individuals on daily aspirin therapy indicate a greater risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

“We’ve taken another critical step forward in expanding the potential market for the AspirinWorks Test,” said Douglass Simpson, Corgenix President and CEO. “The next step in this process will be the launch of the new fully automated immunoturbidimetric (IT) format, making it easier and faster to process large volumes of this important cardiovascular test.”

Once completed and granted market clearance by the FDA, the new IT assay for 11dhTxB2 will be compatible with automated chemistry analyzers, making the test readily available in most

hospital laboratories. The assay will be manufactured at Randox Laboratories in the United Kingdom, and the two companies will share global distribution rights.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for vascular diseases, immunology disorders, and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 52 diagnostic products through a global distribution. More information is available at www.corgenix.com.

About Randox Laboratories

Randox is an international diagnostics company, headquartered in the UK. Currently the twenty- third largest diagnostics company in the world, Randox develops, manufactures and markets clinical diagnostic products worldwide. Core products are: Biochip Array Technology; clinical chemistry analyzers and reagents; quality controls and external quality assurance programs; environmental diagnostics; recombinant proteins and antibodies. More information is available at www.randox.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Media Contact:

Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
Email: dan@armadamedical.com

Company Contact:

Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Corgenix Highlights AspirinWorks® Test at Pri-Med South 2011

PRESS RELEASE

For Immediate Release
Corgenix Highlights AspirinWorks® Test at Pri-Med South 2011

Simple, non-invasive test measures aspirin effect

DENVER — February 9, 2011 — Anti-platelet therapy and testing for aspirin effect are sure to be discussed at the February 10–13 Pri-Med® South 2011 conference in Fort Lauderdale, Fla. During the conference, Corgenix Medical Corp. (OTC BB: CONX) will highlight its AspirinWorks® Test for aspirin effect in booth No. 902 at the Broward County Convention Center.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen. It is the only FDA-cleared test that helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring the urine levels of 11-dehydro thromboxane B2 (11-dhTxB2), a metabolite of thromboxane, the target of aspirin therapy. Individuals with high levels of 11- dhTxB2 are at increased risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

“Not everyone responds the same to the same dose of aspirin, and this test recognizes that fact,” said Gordon Ens, Clinical Affairs Director for Corgenix Medical Corp. “Aspirin effect is real, it can be measured, and it can be effectively treated by increasing dosage or changing therapy.”

Corgenix representatives will be on-hand during the conference to answer questions about the AspirinWorks Test, which will be offered to qualified attendees during regular exhibit hours February 11-13 in booth No. 902. Test results will be provided after the conference.

The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories, including Quest Diagnostics, LabCorp, SpectraCell, Health Diagnostic Laboratory and others.

Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient. Physicians and laboratories interested in ordering the test can call 1-800- 729-5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Media Contact:
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
Email: dan@armadamedical.com

Randox Laboratories Completed Feasibility

For Immediate Release

PRESS RELEASE

Randox Laboratories Completed Feasibility

Clinical Laboratory Fee Schedule boosts reimbursement for AspirinWorks,
the only FDA-cleared test that measures urinary 11dhTxB2 to assess aspirin effect

DENVER — January 6, 2011 — The AspirinWorks® Test from Corgenix Medical Corporation (OTC BB: CONX), reimbursed under CPT code 84431, has received a 28 percent increase in reimbursement according to the 2011 Clinical Laboratory Fee Schedule. The fee schedule is published annually by the Centers for Medicare and Medicaid Services (CMS).

“This is encouraging news for the AspirinWorks Test, and it accurately reflects a more reasonable reimbursement rate for clinical laboratories,” said Douglass Simpson, Corgenix President and Chief Executive Officer. “The increased reimbursement rate should enable more medium-sized clinical laboratories to enter the market, increasing the number of labs that run the AspirinWorks Test.”

The AspirinWorks Test is the only FDA-cleared test to measure thromboxane metabolites. It is reimbursed for clinical laboratories under two Current Procedural Terminology (CPT) codes. CPT codes are the most widely accepted form of medical nomenclature used to report medical procedures and services.

Clinical laboratories that run the AspirinWorks Test use a combination of two codes: 84431 for thromboxane metabolites (also known as AspirinWorks/11dhTxB2) and 82570 for the urinary creatinine measurement. The CMS National Limit for CPT code 84431 was increased 30 percent over the 2010 rate; however, a two percent across-the-board reduction for CMS tests in the CPT system resulted in an overall 19 percent increase in total clinical laboratory reimbursement for the AspirinWorks Test from $25.95 in 2010 to $30.92 in 2011.

The AspirinWorks Test is the only FDA-cleared test that measures urinary 11dhTxB2 to determine aspirin effect in apparently healthy individuals post ingestion. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy. Numerous peer-reviewed studies have shown that not everyone benefits from the same dose of aspirin.

Launched in the U.S. in June 2007 following FDA 510(k) clearance, the AspirinWorks Test is available nationwide through major medical laboratories. Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe,” “estimate,” “project,” “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
E-mail : wcritchfield@corgenix.com

Media Contact:
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
E-mail: dan@armadamedical.com

Corgenix to Exhibit AspirinWorks® at Pri-Med East

PRESS RELEASE

For Immediate Release
Corgenix to Exhibit AspirinWorks® Test at Pri-Med East

Test measures urinary 11dhTxB2 to assess aspirin effect

DENVER— November 17, 2010 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting and offering complimentary testing for its AspirinWorks® Test at Pri-Med East 2010. The conference and exhibit will take place November 18-21 at the Boston Convention and Exhibition Center.

Corgenix representatives will be on-hand during the conference at booth No. 1012 to answer questions about the AspirinWorks Test, including availability of the test, the latest supporting clinical data and ordering information. AspirinWorks Tests will be offered to qualified attendees during regular exhibit hours November 19-21. Test results will be provided after the conference.

The AspirinWorks Test is the only FDA-cleared test that measures urinary 11dhTxB2 to determine aspirin effect in apparently healthy individuals post ingestion. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy. Numerous studies in the literature have shown that not everyone benefits from the same dose of aspirin.

The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance and is now available nationwide through major medical laboratories, including Quest, LabCorp, SpectraCell and Health Diagnostic Laboratory, Inc. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin for prevention.

Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be

obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Media Contact:
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
Email: dan@armadamedical.com

Corgenix Announces Issuance of U.S. Patent for AspirinWorks® (11-dehydro thromboxane B2)

For Immediate Release

PRESS RELEASE

Corgenix Announces Issuance of U.S. Patent for AspirinWorks® (11-dehydro thromboxane B2)

New patent strengthens Corgenix intellectual
property portfolio, demonstrates accuracy of AspirinWorks Test

DENVER — June 24, 2010 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks® technology and product line.

The patent, issued June 1, 2010, covers the AspirinWorks Test and represents the latest addition to Corgenix intellectual property (IP) portfolio. AspirinWorks is the only FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2 (TxA2), the target of aspirin therapy. The test targets a potential global market exceeding 200 million individuals.

U.S. Patent No. 7,727,730 B2, “Methods and Kits for Detection of Thromboxane A2 Metabolites,” recognizes the ability of the AspirinWorks Test to accurately measure additional biomarkers of platelet inhibition. Specifically, the patent relates to the AspirinWorks Test’s ability to more accurately depict the true levels of circulating TxA2, a chemical that activates platelets and causes them to stick together.

“This patent further strengthens our strategic position in this important aspect of clinical testing,” said Douglass Simpson, Corgenix President and Chief Executive Officer. “By adding this patent to our already strong IP portfolio, Corgenix remains in a premier competitive position as this market continues to evolve.”

More than 1 million Americans experience new or recurrent heart attacks each year. At-risk individuals are eligible for aspirin therapy and should be tested for the presence or absence of the therapy’s effect.

Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or e-mail info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.

Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
E-mail: wcritchfield@corgenix.com

Media Contact:
Armada Medical Marketing
Dan Snyders
Phone: 303-623-1190 x230 E-mail: dan@armadamedical.com

Corgenix to Exhibit AspirinWorks® Test at Pri-Med New York

PRESS RELEASE

For Immediate Release
Corgenix to Exhibit AspirinWorks® Test at Pri-Med New York

Test measures urinary 11dhTxB2 to assess aspirin effect

DENVER— June 15, 2010 — Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced it will be exhibiting its AspirinWorks® Test June 17-19 at the Pri-Med New York 2010 conference. The meeting will take place at the Jacob K. Javits Convention Center in New York, N.Y.

Corgenix representatives will be on-hand during the conference at booth No. 700 to answer questions about the AspirinWorks Test, including availability of the test, the latest supporting clinical data and ordering information. Complimentary AspirinWorks Tests will be offered to qualified attendees during regular exhibit hours June 17-19. Test results will be provided after the conference.

The AspirinWorks Test is the only FDA-cleared test that measures urinary 11dhTxB2 to accurately determine the effect of aspirin in apparently healthy individuals. 11dhTxB2 is a metabolite of thromboxane A2, the target of aspirin therapy.

The AspirinWorks Test was launched in the U.S. in June 2007 following FDA 510(k) clearance, and it is now available nationwide through major medical laboratories, including Quest, LabCorp, SpectraCell and Health Diagnostic Laboratory, Inc. The test targets a potential U.S. market of over 60 million individuals and a potential global market exceeding 200 million individuals who take aspirin for prevention.

Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be

obtained in any doctor’s office or patient service center, making the test convenient for both physician and patient.

Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’ s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’ s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Company Contact:
Corgenix Medical Corp.
William Critchfield, Senior VP and CFO Phone: 303-453-8903
Email: wcritchfield@corgenix.com

Media Contact:
Armada Medical Marketing
Dan Snyders, Vice President and Public Relations Supervisor Phone: 303-623-1190 x230
Email: dan@armadamedical.com